Researchers developed BsPNEC, a bispecific peptide-nanozyme conjugate targeting PD-L1 and CXCR1/2. It disrupts immunosuppression, activates the cGAS-STING pathway via ROS to boost T cell infiltration, and enables MRI. It effectively treats resistant pancreatic cancer.

References:

• Chen D, Xu R, Ye X, et al. Design of a bispecific peptide-nanozyme conjugate for cancer immunotherapy[J]. Cell Reports Medicine, 2026.